IBDEI2DU ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,40427,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,40427,1,1,0)
 ;;=1^90791
 ;;^UTILITY(U,$J,358.3,40427,1,2,0)
 ;;=2^Psychiatric Diagnostic Evaluation     
 ;;^UTILITY(U,$J,358.3,40428,0)
 ;;=90792^^158^1987^2^^^^1
 ;;^UTILITY(U,$J,358.3,40428,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,40428,1,1,0)
 ;;=1^90792
 ;;^UTILITY(U,$J,358.3,40428,1,2,0)
 ;;=2^Psychiatric Diagnostic Eval w/ Med Svc
 ;;^UTILITY(U,$J,358.3,40429,0)
 ;;=B18.2^^159^1988^26
 ;;^UTILITY(U,$J,358.3,40429,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40429,1,3,0)
 ;;=3^Hepatitis C,Chr
 ;;^UTILITY(U,$J,358.3,40429,1,4,0)
 ;;=4^B18.2
 ;;^UTILITY(U,$J,358.3,40429,2)
 ;;=^5000548
 ;;^UTILITY(U,$J,358.3,40430,0)
 ;;=C44.99^^159^1988^50
 ;;^UTILITY(U,$J,358.3,40430,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40430,1,3,0)
 ;;=3^Skin Cancer,Unspec
 ;;^UTILITY(U,$J,358.3,40430,1,4,0)
 ;;=4^C44.99
 ;;^UTILITY(U,$J,358.3,40430,2)
 ;;=^5001094
 ;;^UTILITY(U,$J,358.3,40431,0)
 ;;=E11.9^^159^1988^15
 ;;^UTILITY(U,$J,358.3,40431,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40431,1,3,0)
 ;;=3^Diabetes Type 2
 ;;^UTILITY(U,$J,358.3,40431,1,4,0)
 ;;=4^E11.9
 ;;^UTILITY(U,$J,358.3,40431,2)
 ;;=^5002666
 ;;^UTILITY(U,$J,358.3,40432,0)
 ;;=E11.40^^159^1988^16
 ;;^UTILITY(U,$J,358.3,40432,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40432,1,3,0)
 ;;=3^Diabetes Type 2 w/ Neuropathy
 ;;^UTILITY(U,$J,358.3,40432,1,4,0)
 ;;=4^E11.40
 ;;^UTILITY(U,$J,358.3,40432,2)
 ;;=^5002644
 ;;^UTILITY(U,$J,358.3,40433,0)
 ;;=E78.2^^159^1988^27
 ;;^UTILITY(U,$J,358.3,40433,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40433,1,3,0)
 ;;=3^Hyperlipidemia,Mixed
 ;;^UTILITY(U,$J,358.3,40433,1,4,0)
 ;;=4^E78.2
 ;;^UTILITY(U,$J,358.3,40433,2)
 ;;=^78424
 ;;^UTILITY(U,$J,358.3,40434,0)
 ;;=E78.5^^159^1988^28
 ;;^UTILITY(U,$J,358.3,40434,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40434,1,3,0)
 ;;=3^Hyperlipidemia,Unspec
 ;;^UTILITY(U,$J,358.3,40434,1,4,0)
 ;;=4^E78.5
 ;;^UTILITY(U,$J,358.3,40434,2)
 ;;=^5002969
 ;;^UTILITY(U,$J,358.3,40435,0)
 ;;=E66.3^^159^1988^44
 ;;^UTILITY(U,$J,358.3,40435,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40435,1,3,0)
 ;;=3^Overweight
 ;;^UTILITY(U,$J,358.3,40435,1,4,0)
 ;;=4^E66.3
 ;;^UTILITY(U,$J,358.3,40435,2)
 ;;=^5002830
 ;;^UTILITY(U,$J,358.3,40436,0)
 ;;=D64.9^^159^1988^3
 ;;^UTILITY(U,$J,358.3,40436,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40436,1,3,0)
 ;;=3^Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,40436,1,4,0)
 ;;=4^D64.9
 ;;^UTILITY(U,$J,358.3,40436,2)
 ;;=^5002351
 ;;^UTILITY(U,$J,358.3,40437,0)
 ;;=F17.200^^159^1988^41
 ;;^UTILITY(U,$J,358.3,40437,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40437,1,3,0)
 ;;=3^Nicotine Dependence,Unspec
 ;;^UTILITY(U,$J,358.3,40437,1,4,0)
 ;;=4^F17.200
 ;;^UTILITY(U,$J,358.3,40437,2)
 ;;=^5003360
 ;;^UTILITY(U,$J,358.3,40438,0)
 ;;=F17.229^^159^1988^38
 ;;^UTILITY(U,$J,358.3,40438,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40438,1,3,0)
 ;;=3^Nicotine Dependence,Chewing Tobacco
 ;;^UTILITY(U,$J,358.3,40438,1,4,0)
 ;;=4^F17.229
 ;;^UTILITY(U,$J,358.3,40438,2)
 ;;=^5003374
 ;;^UTILITY(U,$J,358.3,40439,0)
 ;;=F19.10^^159^1988^53
 ;;^UTILITY(U,$J,358.3,40439,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40439,1,3,0)
 ;;=3^Substance Abuse,Unspec
 ;;^UTILITY(U,$J,358.3,40439,1,4,0)
 ;;=4^F19.10
 ;;^UTILITY(U,$J,358.3,40439,2)
 ;;=^5003416
 ;;^UTILITY(U,$J,358.3,40440,0)
 ;;=F15.10^^159^1988^52
 ;;^UTILITY(U,$J,358.3,40440,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40440,1,3,0)
 ;;=3^Stimulant Abuse,Unspec
 ;;^UTILITY(U,$J,358.3,40440,1,4,0)
 ;;=4^F15.10
 ;;^UTILITY(U,$J,358.3,40440,2)
 ;;=^5003282
